Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This modified glass ionomer cement (GIC) is an experimental dental restorative material developed by researchers at Ain Shams University for the treatment of dental caries, particularly in primary molars. The modification involves the incorporation of low molecular weight chitosan, a natural polysaccharide biopolymer, into the liquid phase and titanium dioxide (TiO2) nanoparticles into the powder phase of conventional glass ionomer cement. This biomaterial is designed to enhance the antibacterial properties of the cement against cariogenic bacteria such as *Streptococcus mutans* and *Lactobacillus* species, which are primary contributors to dental caries. The material is specifically being evaluated for its clinical performance and antimicrobial efficacy in indirect pulp capping procedures, aiming to reduce secondary caries and improve the longevity of dental restorations in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chitosan + titanium dioxide + glass ionomer cement.